Olympian Clinical Research
AUGUST 19, 2022
About 30% of children with eczema have a food allergy, and many children may develop asthma or hay fever. Insomnia, allergies, and asthma may also be more common in children with eczema. The Benefits of Clinical Research for Pediatric Dermatology Conditions. Symptoms of Pediatric Eczema. Leathery patches of skin.
The Pharma Data
JANUARY 12, 2021
Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. He has in depth Global Development Expertise (e.g.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
DECEMBER 9, 2020
Clobetasone has a narrow licensed use. Dactacort has also antibacterial properties and is one of few over the counter creams licensed for bacterial infections. An interesting licensed use for Eurax cream is the treatment of scabies and itchy skin infestation in the skin. E45 Dermatological Itch Relief Cream, 100g.
The Pharma Data
MAY 18, 2021
This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. The performance remained ahead of competition with growth momentum in the Dermatology and Nutritionals categories, with business up by 6.6
The Pharma Data
FEBRUARY 5, 2021
American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. Ask your patient about any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies. For more information and to find a provider near you, visit [link].
XTalks
AUGUST 2, 2023
Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.
The Pharma Data
JANUARY 24, 2021
It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.
Expert insights. Personalized for you.
52 
Let's personalize your content